Enrolling by invitationPhase 3NCT07073014
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Studying Hypochondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Intervention
- Vosoritide(drug)
- Enrollment
- 140 target
- Eligibility
- All sexes
- Timeline
- 2025 – 2040
Study locations (23)
- Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children), Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Murdoch Children's Research Institute, Parkville, Victoria, Australia
- University of Alberta Stollery Children's Hospital, Edmonton, Alberta, Canada
- SickKids - The Hospital for Sick Children, Toronto, Ontario, Canada
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
- Hospices Civils de Lyon - Hopital Femme Mere Enfant, Lyon, France
- Hopital de la Timone, Marseille, France
- Hopital Necker-Enfants Malade, Paris, France
- CHU de Toulouse, Toulouse, France
- Uniklinik Koln, Cologne, Germany
- Univeristatskinderklinik Magdeburg, Magdeburg, Germany
- Instituto Giannina Gaslini, Genoa, Italy
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07073014 on ClinicalTrials.govOther trials for Hypochondroplasia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07393373Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- RECRUITINGPHASE2NCT07126262A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT06410976Prospective Clinical Assessment Study in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- RECRUITINGNCT06212947A Multicenter Multinational Observational Study of Children With HypochondroplasiaBioMarin Pharmaceutical